{
    "xml": "<topic id=\"PHP3397\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/ceftriaxone\" basename=\"ceftriaxone\" title=\"CEFTRIAXONE\">\n<title>CEFTRIAXONE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_151\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/cephalosporins/ceftriaxone\">Ceftriaxone</xref>\n</p>\n<data name=\"vtmid\">19841008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_341352686\" title=\"Cephalosporins\">Cephalosporins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34534\" title=\"CEPHALOSPORINS\" namespace=\"/drug-classes/cephalosporins\">CEPHALOSPORINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP46196\" outputclass=\"indicationsAndDose\" rev=\"1.68\" parent=\"/drugs/ceftriaxone\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Surgical prophylaxis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;g for 1 dose, dose to be administered up to 30 minutes before procedure.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis before colorectal surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8239;g for 1 dose, dose to be administered up to 30 minutes before procedure, intramuscular doses over 1&#8239;g divided between more than one site.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Uncomplicated gonorrhoea</p>\n<p outputclass=\"therapeuticIndication\">Pelvic inflammatory disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>500&#8239;mg for 1 dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Early syphilis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>500&#8239;mg daily for 10 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8211;4&#8239;g daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection or by intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;g daily; increased to 2&#8211;4&#8239;g daily, increased dose to be used for severe infections, intramuscular doses over 1&#8239;g divided between more than one site, single intravenous doses above 1&#8239;g to be administered by intravenous infusion only.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Meningitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;11 years (body-weight up to 50 kg)</p>\n<p>50&#8211;80&#8239;mg/kg daily, doses of 50&#8239;mg/kg and over to be administered by intravenous infusion only.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1 month&#8211;11 years (body-weight 50 kg and above)</p>\n<p>2&#8211;4&#8239;g daily, intramuscular doses over 1&#8239;g divided between more than one site, single intravenous doses above 1&#8239;g to be administered by intravenous infusion only.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>2&#8211;4&#8239;g daily, intramuscular doses over 1&#8239;g divided between more than one site, single intravenous doses above 1&#8239;g to be administered by intravenous infusion only.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of secondary case of meningococcal meningitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>250&#8239;mg for 1 dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of secondary case of <ph outputclass=\"organism\">\n<i>\n<i>Haemophilus influenzae</i>\n</i>\n</ph> type b disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;g daily for 2 days.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46115\" outputclass=\"unlicensedUse\" rev=\"1.14\" parent=\"/drugs/ceftriaxone\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Not licensed for prophylaxis of meningococcal meningitis or <i>Haemophilus influenzae</i> type b disease.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Not licensed for congenital gonococcal conjunctivitis or early syphilis.</p>\n<p>Not licensed for use in children under 12 years of age for uncomplicated gonorrhoea or pelvic inflammatory disease.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Not licensed for early syphilis.</p>\n<p>Not licensed for endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial).</p>\n<p>Dose not licensed for treatment of uncomplicated gonorrhoea or pelvic inflammatory disease in adults over 18 years.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46296\" outputclass=\"contraindications\" rev=\"1.18\" parent=\"/drugs/ceftriaxone\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Concomitant treatment with intravenous calcium (including total parenteral nutrition containing calcium) in neonates over 41 weeks corrected gestational age&#8212;risk of precipitation in urine and lungs</ph> (in neonates); <ph outputclass=\"contraindication\">neonates less than 41 weeks corrected gestational age</ph> (in neonates); <ph outputclass=\"contraindication\">neonates over 41 weeks corrected gestational age with jaundice, hypoalbuminaemia, acidosis, unconjugated hyperbilirubinaemia, or impaired bilirubin binding</ph> (in neonates)</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46328\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/ceftriaxone\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Dehydration (risk of ceftriaxone precipitation in gall bladder)</ph>; <ph outputclass=\"caution\">may displace bilirubin from serum albumin, administer over 60 minutes in neonates</ph> (in neonates); <ph outputclass=\"caution\">treatment longer than 14 days</ph>; <ph outputclass=\"caution\">use with caution in neonates</ph> (in neonates)</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46129\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/ceftriaxone\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Calcium ceftriaxone precipitates in gall bladder&#8212;consider discontinuation if symptomatic</ph>; <ph outputclass=\"sideEffect\">calcium ceftriaxone precipitates in urine (particularly in very young, dehydrated or those who are immobilised)&#8212;consider discontinuation if symptomatic</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Pancreatitis</ph>; <ph outputclass=\"sideEffect\">prolongation of prothrombin time</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46167\" outputclass=\"pregnancy\" parent=\"/drugs/ceftriaxone\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Not known to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46343\" outputclass=\"breastFeeding\" parent=\"/drugs/ceftriaxone\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk in low concentration, but appropriate to use.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46244\" outputclass=\"hepaticImpairment\" parent=\"/drugs/ceftriaxone\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose if both hepatic and severe renal impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Monitor plasma concentration if both hepatic and severe renal impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46140\" outputclass=\"renalImpairment\" parent=\"/drugs/ceftriaxone\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Reduce dose if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (max. 2&#8239;g daily).</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Max. 50&#8239;mg/kg daily (max. 2&#8239;g daily) in severe renal impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution in renal failure.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p>Monitor plasma concentration if both hepatic and severe renal impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46385\" outputclass=\"directionsForAdministration\" rev=\"1.28\" parent=\"/drugs/ceftriaxone\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous injection</i>, give over at least 2&#8211;4 minutes.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>For <i>intravenous infusion</i>, dilute reconstituted solution with Glucose 5% or 10% <i>or</i> Sodium Chloride 0.9%; give over at least 30 minutes (60 minutes in neonates).</p>\n<p>Not to be given simultaneously with parenteral nutrition or infusion fluids containing calcium, even by different infusion lines; may be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.</p>\n<p>Displacement value may be significant, consult local guidelines.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use in children</p>\n<p>For <i>intramuscular injection</i> ceftriaxone may be mixed with 1% Lidocaine Hydrochloride Injection to reduce pain at intramuscular injection site; final concentration 250&#8211;350&#8239;mg/mL. Displacement value may be significant, consult local guidelines.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>For <i>intravenous infusion</i> (<i>Rocephin</i>\n<tm tmtype=\"reg\"/>; <i>Ceftriaxone Injection</i>, Genus), give intermittently <i>or via</i> drip tubing <i>in</i> Glucose 5% or 10% <i>or</i> Sodium chloride 0.9%.</p>\n<p>Reconstitute 2-g vial with 40&#8239;mL infusion fluid. Give by intermittent infusion over at least 30 minutes (60 minutes in neonates).</p>\n<p>Not to be given simultaneously with total parenteral nutrition or infusion fluids containing calcium, even by different infusion lines. May be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3397-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ceftriaxone\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: infusion</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76112\" title=\"Powder for solution for injection\" namespace=\"/drugs/ceftriaxone/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78125\" namespace=\"/treatment-summaries/gastro-intestinal-system-infections-bacterial\" title=\"Gastro-intestinal system infections, bacterial\" count=\"1\" rel=\"backlink\">Gastro-intestinal system infections, bacterial</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78145\" namespace=\"/treatment-summaries/cephalosporins\" title=\"Cephalosporins\" count=\"5\" rel=\"backlink\">Cephalosporins</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78210\" namespace=\"/treatment-summaries/antibacterials-use-for-prophylaxis\" title=\"Antibacterials, use for prophylaxis\" count=\"2\" rel=\"backlink\">Antibacterials, use for prophylaxis</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78245\" namespace=\"/treatment-summaries/lyme-disease\" title=\"Lyme disease\" count=\"1\" rel=\"backlink\">Lyme disease</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78484\" namespace=\"/treatment-summaries/musculoskeletal-system-infections-bacterial\" title=\"Musculoskeletal system infections, bacterial\" count=\"1\" rel=\"backlink\">Musculoskeletal system infections, bacterial</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78491\" namespace=\"/treatment-summaries/blood-infections-bacterial\" title=\"Blood infections, bacterial\" count=\"2\" rel=\"backlink\">Blood infections, bacterial</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78529\" namespace=\"/treatment-summaries/genital-system-infections-bacterial\" title=\"Genital system infections, bacterial\" count=\"5\" rel=\"backlink\">Genital system infections, bacterial</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78553\" namespace=\"/treatment-summaries/central-nervous-system-infections-bacterial\" title=\"Central nervous system infections, bacterial\" count=\"5\" rel=\"backlink\">Central nervous system infections, bacterial</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78577\" namespace=\"/treatment-summaries/respiratory-system-infections-bacterial\" title=\"Respiratory system infections, bacterial\" count=\"2\" rel=\"backlink\">Respiratory system infections, bacterial</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78592\" namespace=\"/treatment-summaries/cardiovascular-system-infections-bacterial\" title=\"Cardiovascular system infections, bacterial\" count=\"1\" rel=\"backlink\">Cardiovascular system infections, bacterial</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_151\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/cephalosporins/ceftriaxone\" title=\"Ceftriaxone\" count=\"1\" rel=\"link\">Ceftriaxone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34534\" namespace=\"/drug-classes/cephalosporins\" title=\"CEPHALOSPORINS\" count=\"1\" rel=\"link\">CEPHALOSPORINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76112\" namespace=\"/drugs/ceftriaxone/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP3397",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/ceftriaxone",
    "basename": "ceftriaxone",
    "title": "CEFTRIAXONE",
    "interactants": [
        {
            "id": "bnf_int_151",
            "label": "Ceftriaxone"
        }
    ],
    "vtmid": "19841008",
    "drugClassification": [
        "Cephalosporins"
    ],
    "inheritsFromClass": [
        "CEPHALOSPORINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Surgical prophylaxis",
                        "html": "Surgical prophylaxis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection or intravenous injection"
                    ],
                    "textContent": "By deep intramuscular injection or by intravenous injection",
                    "html": "By deep intramuscular injection or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "1 g for 1 dose, dose to be administered up to 30 minutes before procedure.",
                        "html": "<p>1&#8239;g for 1 dose, dose to be administered up to 30 minutes before procedure.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis before colorectal surgery",
                        "html": "Prophylaxis before colorectal surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection or intravenous infusion"
                    ],
                    "textContent": "By deep intramuscular injection or by intravenous infusion",
                    "html": "By deep intramuscular injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "2 g for 1 dose, dose to be administered up to 30 minutes before procedure, intramuscular doses over 1 g divided between more than one site.",
                        "html": "<p>2&#8239;g for 1 dose, dose to be administered up to 30 minutes before procedure, intramuscular doses over 1&#8239;g divided between more than one site.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Uncomplicated gonorrhoea",
                        "html": "Uncomplicated gonorrhoea"
                    },
                    {
                        "textContent": "Pelvic inflammatory disease",
                        "html": "Pelvic inflammatory disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "500 mg for 1 dose.",
                        "html": "<p>500&#8239;mg for 1 dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Early syphilis",
                        "html": "Early syphilis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "500 mg daily for 10 days.",
                        "html": "<p>500&#8239;mg daily for 10 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial)",
                        "html": "Endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "2&#8211;4 g daily.",
                        "html": "<p>2&#8211;4&#8239;g daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria",
                        "html": "Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection or intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By deep intramuscular injection or by intravenous injection or by intravenous infusion",
                    "html": "By deep intramuscular injection or by intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1 g daily; increased to 2&#8211;4 g daily, increased dose to be used for severe infections, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only.",
                        "html": "<p>1&#8239;g daily; increased to 2&#8211;4&#8239;g daily, increased dose to be used for severe infections, intramuscular doses over 1&#8239;g divided between more than one site, single intravenous doses above 1&#8239;g to be administered by intravenous infusion only.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Meningitis",
                        "html": "Meningitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection or intravenous infusion"
                    ],
                    "textContent": "By deep intramuscular injection or by intravenous infusion",
                    "html": "By deep intramuscular injection or by intravenous infusion"
                },
                "child": [
                    {
                        "textContent": "50&#8211;80 mg/kg daily, doses of 50 mg/kg and over to be administered by intravenous infusion only.",
                        "html": "<p>50&#8211;80&#8239;mg/kg daily, doses of 50&#8239;mg/kg and over to be administered by intravenous infusion only.</p>",
                        "ageGroup": "1 month&#8211;11 years (body-weight up to 50 kg)"
                    },
                    {
                        "textContent": "2&#8211;4 g daily, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only.",
                        "html": "<p>2&#8211;4&#8239;g daily, intramuscular doses over 1&#8239;g divided between more than one site, single intravenous doses above 1&#8239;g to be administered by intravenous infusion only.</p>",
                        "ageGroup": "1 month&#8211;11 years (body-weight 50 kg and above)"
                    },
                    {
                        "textContent": "2&#8211;4 g daily, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only.",
                        "html": "<p>2&#8211;4&#8239;g daily, intramuscular doses over 1&#8239;g divided between more than one site, single intravenous doses above 1&#8239;g to be administered by intravenous infusion only.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of secondary case of meningococcal meningitis",
                        "html": "Prevention of secondary case of meningococcal meningitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "250 mg for 1 dose.",
                        "html": "<p>250&#8239;mg for 1 dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of secondary case of Haemophilus influenzae type b disease",
                        "html": "Prevention of secondary case of <ph outputclass=\"organism\"> <i> <i>Haemophilus influenzae</i> </i> </ph> type b disease",
                        "organism": "Haemophilus influenzae"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection or intravenous injection"
                    ],
                    "textContent": "By intramuscular injection or by intravenous injection",
                    "html": "By intramuscular injection or by intravenous injection",
                    "organism": "Haemophilus influenzae"
                },
                "adult": [
                    {
                        "textContent": "1 g daily for 2 days.",
                        "html": "<p>1&#8239;g daily for 2 days.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Not licensed for prophylaxis of meningococcal meningitis or Haemophilus influenzae type b disease.",
                "html": "<p>Not licensed for prophylaxis of meningococcal meningitis or <i>Haemophilus influenzae</i> type b disease.</p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Not licensed for congenital gonococcal conjunctivitis or early syphilis.\n\nNot licensed for use in children under 12 years of age for uncomplicated gonorrhoea or pelvic inflammatory disease.",
                "html": "<p>Not licensed for congenital gonococcal conjunctivitis or early syphilis.</p><p>Not licensed for use in children under 12 years of age for uncomplicated gonorrhoea or pelvic inflammatory disease.</p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Not licensed for early syphilis.\n\nNot licensed for endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial).\n\nDose not licensed for treatment of uncomplicated gonorrhoea or pelvic inflammatory disease in adults over 18 years.",
                "html": "<p>Not licensed for early syphilis.</p><p>Not licensed for endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial).</p><p>Dose not licensed for treatment of uncomplicated gonorrhoea or pelvic inflammatory disease in adults over 18 years.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Concomitant treatment with intravenous calcium (including total parenteral nutrition containing calcium) in neonates over 41 weeks corrected gestational age&#8212;risk of precipitation in urine and lungs in neonates",
                "html": "Concomitant treatment with intravenous calcium (including total parenteral nutrition containing calcium) in neonates over 41 weeks corrected gestational age&#8212;risk of precipitation in urine and lungs in neonates",
                "specificity": {
                    "patientType": "neonates"
                }
            },
            {
                "type": "contraindications",
                "textContent": "neonates less than 41 weeks corrected gestational age in neonates",
                "html": "neonates less than 41 weeks corrected gestational age in neonates",
                "specificity": {
                    "patientType": "neonates"
                }
            },
            {
                "type": "contraindications",
                "textContent": "neonates over 41 weeks corrected gestational age with jaundice, hypoalbuminaemia, acidosis, unconjugated hyperbilirubinaemia, or impaired bilirubin binding in neonates",
                "html": "neonates over 41 weeks corrected gestational age with jaundice, hypoalbuminaemia, acidosis, unconjugated hyperbilirubinaemia, or impaired bilirubin binding in neonates",
                "specificity": {
                    "patientType": "neonates"
                }
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Dehydration (risk of ceftriaxone precipitation in gall bladder)",
                "html": "Dehydration (risk of ceftriaxone precipitation in gall bladder)"
            },
            {
                "type": "cautions",
                "textContent": "may displace bilirubin from serum albumin, administer over 60 minutes in neonates in neonates",
                "html": "may displace bilirubin from serum albumin, administer over 60 minutes in neonates in neonates",
                "specificity": {
                    "patientType": "neonates"
                }
            },
            {
                "type": "cautions",
                "textContent": "treatment longer than 14 days",
                "html": "treatment longer than 14 days"
            },
            {
                "type": "cautions",
                "textContent": "use with caution in neonates in neonates",
                "html": "use with caution in neonates in neonates",
                "specificity": {
                    "patientType": "neonates"
                }
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Calcium ceftriaxone precipitates in gall bladder&#8212;consider discontinuation if symptomatic",
                        "html": "Calcium ceftriaxone precipitates in gall bladder&#8212;consider discontinuation if symptomatic",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "calcium ceftriaxone precipitates in urine (particularly in very young, dehydrated or those who are immobilised)&#8212;consider discontinuation if symptomatic",
                        "html": "calcium ceftriaxone precipitates in urine (particularly in very young, dehydrated or those who are immobilised)&#8212;consider discontinuation if symptomatic",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Pancreatitis",
                        "html": "Pancreatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "prolongation of prothrombin time",
                        "html": "prolongation of prothrombin time",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Not known to be harmful.",
                "html": "<p>Not known to be harmful.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk in low concentration, but appropriate to use.",
                "html": "<p>Present in milk in low concentration, but appropriate to use.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose if both hepatic and severe renal impairment.",
                "html": "<p>Reduce dose if both hepatic and severe renal impairment.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor plasma concentration if both hepatic and severe renal impairment.",
                "html": "<p>Monitor plasma concentration if both hepatic and severe renal impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Reduce dose if eGFR less than 10 mL/minute/1.73 m2 (max. 2 g daily).",
                "html": "<p>Reduce dose if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (max. 2&#8239;g daily).</p>"
            },
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Max. 50 mg/kg daily (max. 2 g daily) in severe renal impairment.",
                "html": "<p>Max. 50&#8239;mg/kg daily (max. 2&#8239;g daily) in severe renal impairment.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution in renal failure.",
                "html": "<p>Use with caution in renal failure.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor plasma concentration if both hepatic and severe renal impairment.",
                "html": "<p>Monitor plasma concentration if both hepatic and severe renal impairment.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous injection, give over at least 2&#8211;4 minutes.",
                "html": "<p>For <i>intravenous injection</i>, give over at least 2&#8211;4 minutes.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion, dilute reconstituted solution with Glucose 5% or 10% or Sodium Chloride 0.9%; give over at least 30 minutes (60 minutes in neonates).\n\nNot to be given simultaneously with parenteral nutrition or infusion fluids containing calcium, even by different infusion lines; may be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.\n\nDisplacement value may be significant, consult local guidelines.",
                "html": "<p>For <i>intravenous infusion</i>, dilute reconstituted solution with Glucose 5% or 10% <i>or</i> Sodium Chloride 0.9%; give over at least 30 minutes (60 minutes in neonates).</p><p>Not to be given simultaneously with parenteral nutrition or infusion fluids containing calcium, even by different infusion lines; may be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.</p><p>Displacement value may be significant, consult local guidelines.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intramuscular use in children",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intramuscular"
                    ]
                },
                "textContent": "For intramuscular injection ceftriaxone may be mixed with 1% Lidocaine Hydrochloride Injection to reduce pain at intramuscular injection site; final concentration 250&#8211;350 mg/mL. Displacement value may be significant, consult local guidelines.",
                "html": "<p>For <i>intramuscular injection</i> ceftriaxone may be mixed with 1% Lidocaine Hydrochloride Injection to reduce pain at intramuscular injection site; final concentration 250&#8211;350&#8239;mg/mL. Displacement value may be significant, consult local guidelines.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Rocephin ; Ceftriaxone Injection, Genus), give intermittently or via drip tubing in Glucose 5% or 10% or Sodium chloride 0.9%.\n\nReconstitute 2-g vial with 40 mL infusion fluid. Give by intermittent infusion over at least 30 minutes (60 minutes in neonates).\n\nNot to be given simultaneously with total parenteral nutrition or infusion fluids containing calcium, even by different infusion lines. May be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Rocephin</i>\n<tm tmtype=\"reg\"/>; <i>Ceftriaxone Injection</i>, Genus), give intermittently <i>or via</i> drip tubing <i>in</i> Glucose 5% or 10% <i>or</i> Sodium chloride 0.9%.</p><p>Reconstitute 2-g vial with 40&#8239;mL infusion fluid. Give by intermittent infusion over at least 30 minutes (60 minutes in neonates).</p><p>Not to be given simultaneously with total parenteral nutrition or infusion fluids containing calcium, even by different infusion lines. May be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "infusion"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76112",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78125",
                "label": "Gastro-intestinal system infections, bacterial",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78145",
                "label": "Cephalosporins",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78210",
                "label": "Antibacterials, use for prophylaxis",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78245",
                "label": "Lyme disease",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78484",
                "label": "Musculoskeletal system infections, bacterial",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78491",
                "label": "Blood infections, bacterial",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78529",
                "label": "Genital system infections, bacterial",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78553",
                "label": "Central nervous system infections, bacterial",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78577",
                "label": "Respiratory system infections, bacterial",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78592",
                "label": "Cardiovascular system infections, bacterial",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_151",
                "label": "Ceftriaxone",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34534",
                "label": "CEPHALOSPORINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76112",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}